Recombinant Anti-CD3 x Anti-CD79B Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD3 and anti-CD79B IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget T cells to tumor cells. It is designed for the research of Chronic lymphocytic leukemia (CLL); Non-Hodgkin's lymphoma (NHL); Diffuse large B cell lymphoma (DLBCL) therapy.
There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-CD79B Bispecific Antibody (scIgG) (SCIGG-070). Click the button below to contact us or submit your feedback about this product.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRYSERVICES
PRODUCTS
PLATFORMS